tbuckley/cabot-search huggingface dataset:
Complementary and Alternative Medical Education
Authors: Edzard Ernst
Journal: Annals of Internal Medicine (2004)

Letters6 January 2004Complementary and Alternative Medical EducationEdzard Ernst, MD, PhD, FRCP, FRCPEdEdzard Ernst, MD, PhD, FRCP, FRCPEdFrom Complementary Medicine, Peninsula Medical School, Exeter, UK.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-1-200401060-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Wetzel and colleagues (1) make a strong a case for integrating CAM into medical education. Their deliberations are very much centered on the situation in the United States, but it might be interesting to look further and include perspectives from elsewhere. The 3 countries in which I have detailed experience differ considerably in terms of CAM education of (future) medical doctors. In Germany, an element of CAM has long been a compulsory part of the official medical education. Austria seems to be gradually following this model, while in the United Kingdom, CAM is still largely confined to ...References1. Wetzel MS, Kaptchuk TJ, Haramati A, Eisenberg DM. Complementary and alternative medical therapies: implications for medical education. Ann Intern Med. 2003;138:191-6. [PMID: 12558358] LinkGoogle Scholar2. WHO global strategy on traditional and alternative medicine. Public Health Rep. 2002;117:300-1. [PMID: 12452183] MedlineGoogle Scholar3. House of Lords Science and Technology Committee. House of Lords Report: Science and Technology, 6th report. London: The Stationery Office; 2000. Google Scholar Author, Article, and Disclosure InformationAffiliations: From Complementary Medicine, Peninsula Medical School, Exeter, UK. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoComplementary and Alternative Medical Therapies: Implications for Medical Education Miriam S. Wetzel , Ted J. Kaptchuk , Aviad Haramati , and David M. Eisenberg Complementary and Alternative Medical Education Mary P. Guerrera Complementary and Alternative Medical Education Miriam S. Wetzel , Ted J. Kaptchuk , David M. Eisenberg , and Aviad Haramati Complementary and Alternative Medical Education Samuel Neff Complementary and Alternative Medical Education Peter Manu Metrics 6 January 2004Volume 140, Issue 1Page: 68KeywordsForecastingMedical education ePublished: 6 January 2004 Issue Published: 6 January 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Including the poor: the fiscal impacts of Medicaid expansion
Authors: K E Thorpe, J E Siegel, T Dailey
Journal: JAMA (1989)

This article presents the fiscal impacts of the comprehensive reform of the Medicaid program put forth by the Health Policy Agenda for the American People. Proposed reforms include establishment of improved uniform eligibility standards, improvement in the scope and depth of coverage in state Medicaid programs, and increased provider payment rates. We estimate that expanding Medicaid coverage to all currently uninsured nonelderly persons below the federal poverty line would cost approximately $9 billion. A substantial portion of these costs would offset current spending elsewhere in the health care system. Improvement of state packages and increased provider payment could result in sharp increases in costs. We provide a range of estimates considering both the set of benefits provided and the behavior of the private insurance market.The fiscal impacts of the comprehensive reform of the Medicaid program put forth by the Health Policy Agenda for the American People are analyzed. The establishment of improved uniform eligibility standards, improvements in the scope and depth of coverage in state Medicaid programs, and increased provider payment rates would cost $9 billion for all currently uninsured nonelderly persons below the federal poverty line. A range of estimates of cost increases are provided which consider both the set of benefits provided and the behavior of the private insurance market.
Early Clinical Results After Stentless Mitral Valve Implantation and Comparison With Conventional Valve Repair or Replacement
Authors: Thomas Walther, Claudia Walther, Volkmar Falk, Anno Diegeler, Ralf Krakor, Johannes Schneider, Rüdiger Autschbach, Friedrich W. Mohr
Journal: Circulation (1999)

Background —A new quadricusp stentless mitral bioprosthetic valve (QMV) is evaluated and compared with current standards. Methods and Results —Since August 1997, 67 patients were prospectively evaluated: 23 patients received a QMV, 23 had mitral valve repair (MVR), and 21 received conventional mitral valve replacement (MVP). Patient age was 69±8, 64±10, and 62±9 years for QMV, MVR, and MVP treatment, respectively. The underlying pathology was mitral stenosis, incompetence, and mixed disease in a corresponding 8, 9, and 6 patients for QMV, 1, 22, and 0 patients for MVR, and 2, 12, and 7 patients for MVP. The papillary muscles were sufficient in all QMV cases to suspend the valve. Cross-clamp time was 59±19 minutes for QMV implantation. In-hospital mortality for QMV, MVR, and MVP was 1, 0, and 0 patients, respectively, and thoracotomy had to be performed again in 1, 1, and 2 patients, respectively (these outcomes were not valve related). At baseline transthoracic echocardiography, respective maximum flow velocities were 1.6, 1.4, and 1.7 m/s, and valve orifice area was 2.6, 3.5, and 3.4 cm 2 . Mild transvalvular reflux was seen in 8, 7, and 2 patients; moderate reflux, in 1, 1, and 1 patients. Left ventricular ejection fraction was 52%, 54%, and 51% in the respective treatment groups. At follow-up, hemodynamic parameters had further improved in all groups. Conclusions —One year after clinical implantation, the QMV appears to function well and has no additional risks compared with MVR or MVP. The subvalvular apparatus is preserved by suspending the QMV at the papillary muscles; this arrangement is hemodynamically advantageous. Echocardiography reveals an excellent valve performance that resembles native mitral valve morphology and hemodynamic function. The QMV is a promising alternative for biological mitral valve replacement.
JAMES B. HERRICK (1861-1954)
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intractable ascites. Surgical management with reduction in secondary hyperaldosteronism
Authors: J. E. Sampliner
Journal: JAMA (1976)

DESPITE stringent medical therapy, including salt and water restriction and the use of diuretics, salt-poor albumin, and corticosteroids, ascites refractory to treatment develops in an occasional patient with cirrhosis. Because the development of ascites is primarily a mechanical problem, with increased hepatic-outflow vascular resistance,<sup>1</sup>decreased transport capacity for liver lymph, and an increased permeability of hepatic sinusoids, procedures to return ascitic fluid back into the circulatory system have been resorted to in these cases.<sup>2</sup>Recent success with the placement of a peritoneovenous shunt for ascites as described by Le Veen et al<sup>3</sup>led to the use of this shunt in the patient reported here. Studies of aldosterone secretion, not previously described with this form of treatment, were performed on this patient and indicate that this shunt markedly reduces the usual secondary hyperaldosteronism that accompanies massive ascites. <h3>Report of a Case</h3> A 65-year-old man with biopsy-proved Laënnec cirrhosis
World No-Tobacco Day: media is message
Authors: P. Gunby
Journal: JAMA (1994)

NEXT TUESDAY is World No-Tobacco Day. The World Health Organization, an autonomous unit within the United Nations system, has promoted World NoTobacco Day for 7 years in an attempt to "encourage governments, communities, groups, and individuals to become aware of the problem and to take appropriate action." The theme of next week's World No-Tobacco Day is "The [news] Media and Tobacco: Getting the Health Message Across." In recent days, more than ever, that message repeatedly has been printed in newspapers and magazines and broadcast on radio and television. <h3>Media 'Message of Doom'?</h3> It perhaps is understandable if some in the tobacco industry tend to interpret that message as one of doom. This spring's news media accounts of events affecting the industry cannot be cheering to those who make their living from tobacco. For example, it has been reported in the news media that Congress and the Food and Drug Administration
Error in Scale of Y-Axis in Figure 2
Journal: JAMA Psychiatry (2019)

Sho Moriguchi, MD, PhD; Alan A. Wilson, PhD; Laura Miler, HBSc; Pablo M. Rusjan, PhD; Neil Vasdev, PhD; Stephen J. Kish, PhD; Grazyna Rajkowska, PhD; Junming Wang, PhD; Michael Bagby, PhD; Romina Mizrahi, MD; Ben Varughese, BSc; Sylvain Houle, MD, PhD, FRCPC; Jeffrey H. Meyer, MD, PhD, FRCPC
Sleep deprivation and performance of residents
Authors: Timothy B. McCall
Journal: JAMA (1989)

<h3>To the Editor.—</h3> In their article entitled "Sleep Deprivation and Resident Performance," Deaconson et al<sup>1</sup>state, "The strength of our study is its design." They could not be more wrong; the study's design is so flawed that their results and conclusions must be questioned. The subjects were surgical residents working every other night on call. The residents served as their own controls: the study compared them when sleep deprived—after a night on call—with when rested—after a night off. The authors assumed that residents who slept the previous night were rested, but this is hardly a safe assumption. The effects of acute sleep deprivation last far longer than 24 hours.<sup>2</sup>Many residents describe difficulty concentrating "the day after the day after" a night on call—precisely when the rested controls were tested. The authors fail to consider that the control group may also have been sleep deprived, both acutely, as
“Measurements of interrupter resistance: reference values for children 3–13 yrs of age”. P.J.F.M. Merkus, H.G.M. Arets, T. Joosten, A. Siero, M. Brouha, J.Y. Mijnsbergen, J.C. de Jongste, C.K. van der Ent.<i>Eur Respir J</i>2002; 20: 907–911.
Journal: European Respiratory Journal (2002)

Unfortunately, there was an error in equation (3) in the fourth paragraph of the Discussion on page 910.
Abstract 3877: A unique layered 3D stromal tissue model for <i>in vitro</i> evaluation of immunologic agents and immune cell infiltration into microenviroment
Authors: Rii Morimura, Isana Nada, Kei Tsukamoto, Eiji Shinozaki, shiro kitano
Journal: Cancer Research (2020)

Abstract Background The modulation of the immune system is a proven key target for cancer therapy, however, the complex interplay between immune cells and cancer cells in cancer microenvironment remains only partially understood. In addition, the currently available in vitro cancer microenvironment models are not designed to study the immunologic agents and a role of immune cells. Here, we developed a unique layered 3D stromal tissue model comprising immune, stromal and cancer cells. Method Layered 3D stromal tissue model was constructed by culturing fibroblasts and endothelial cells coated with extracellular matrix (ECM) and natural polysaccharide. Morphological analysis of the layered 3D stromal tissues and co-cultured tumor were evaluated by HE stain, immunohistochemistry and immunofluorescence (IF). For cytotoxicity assay, cancer cell lines were seeded on or in the 3D stromal tissue and incubated with peripheral blood mononuclear cell (PBMC) and Programmed cell death 1 (PD-1) blockade with Nivolumab. Remaining cancer cells post drug treatment were quantified by IF and imaging analysis. Result The co-cultured stromal tissues were multi-layered (approximately 20 layers), had microvascular formation. Hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) derived from fibroblast cells played important roles in tube formation. Moreover, the position of cancer cells in 3D stromal tissue was manipulated easily. PBMC infiltration into 3D stromal tissue and the interaction between PBMC and cancer cells were visualized. High level of programmed cell death ligand 1 (PD-L1) expression on cancer cells correlated with a higher response to PD-1 blockade in vitro as well as clinical trials. Conclusion We present a unique layered 3D cell culture system based on stromal/cancer/immune cells to study immunologic agents and immune cell infiltration in cancer microenvironment. Our 3D model has the ability to reflect in vivo conditions closer than 2D model and provide a tool for in vitro tumor infiltrating lymphocyte (TIL) or immunologic agent testing. Citation Format: Rii Morimura, Isana Nada, Kei Tsukamoto, Eiji Shinozaki, shiro kitano. A unique layered 3D stromal tissue model for in vitro evaluation of immunologic agents and immune cell infiltration into microenviroment [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 3877.
PERIODIC PARALYSIS
Journal: JAMA (1963)

What are the basic defects in patients with familial periodic paralysis, and where are these defects located? It has become increasingly clear that hypokalemia in itself is not the primary factor in this disease. Cases have been reported without alteration in serum potassium, and the onset, severity, and remission of attacks are not necessarily related to the degree of hypopotassemia. Solomon,<sup>1</sup>reported in the July issue of the<i>Archives of Neurology</i>, has considered the diencephalic factors which might be present. His study was prompted by the case of a patient who presented features of both periodic paralysis and cataplexy. The diencephalon as a pathophysiological site common to both periodic paralysis and the narcolepsy-cataplexy syndrome is suggested by the similarity of incidence, precipitating factors, and clinical features of the paralysis in the two conditions. Solomon's theory of a central-nervous-system defect in periodic paralysis is supported by the following facts and
Evidence for the Significant Role of Immunoglobulin Light Chains in Antigen Recognition and Selection in Chronic Lymphocytic Leukemia
Authors: Anastasia Hadzidimitriou, Nikos Darzentas, Fiona Murray, Tanja Smilevska, Eleni Arvaniti, Cristina Tresoldi, Athanasios Tsaftaris, Nikolaos Laoutaris, Achilles Anagnostopoulos, Frederic Davi, Paolo Ghia, Richard Rosenquist, Kostas Stamatopoulos, Chrysoula Belessi
Journal: Blood (2008)
AMC 095 (AIDS Malignancy Consortium): A phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV associated solid tumors (ST) with expansion cohorts in HIV associated solid tumors and classical Hodgkin lymphoma (cHL).
Authors: Lakshmi Rajdev, Elizabeth Y. Chiao, Shelly Lensing, Richard F. Little, Dirk Dittmer, Mark H. Einstein, Missak Haigentz, Joseph A. Sparano, Ronald T. Mitsuyasu
Journal: Journal of Clinical Oncology (2018)

TPS2597 Background: Immune checkpoint blockade (ICB) using agents that target the priming phase (i.e. CTLA-4) and effector phase (e.g. PD-1) of host immunity, used individually or in combination, has emerged as a therapeutic strategy for cancers. Little is known about the safety, tolerability and efficacy of ICB in patients (pts) with HIV infection and cancer. Methods: AMC 095 (NCT02408861) is a multicenter, international phase I study of the PD-1 inhibitor, nivo alone or in combination with a CTLA-4 inhibitor, ipi, in 2 cohorts stratified by CD4 counts (Stratum 1: CD4 counts≥200/uL and Stratum 2: CD4 count 100-200/uL) with additional expansion cohorts at the recommended phase II dose in pts with ST and cHL. The primary study objective is to determine the safety and feasibility of nivo alone and the nivo+ipi combination. Secondary objectives are to evaluate the effects of single agent nivo, and ipi+ nivo, on HIV replication and immune function (HIV viral load in plasma using conventional assay, CD4+, and CD8+ cells), and to obtain preliminary information regarding response. Clinical trial information: NCT02408861. The trial was initiated in 8/15, as of 2/2/18, the study is ongoing, and 29 pts have been enrolled. Updated information on the safety and responses will be presented. Funded by the NCI Grant #UM1CA121947. Agent/dose Stratum I-CD4 ≥ 200/uL 2-CD4 < 200 /uL No. Treated Nivo 3 mg/kg q 2 wk 1 6 Nivo 3 mg/kg q 2 wk 2 6 Nivo 240 mg q 2 wk + Ipi 1 mg/kg q 6 wk 1 6 Expansion cohort in Solid Tumors Nivo 240 mg q 2 wk 1/2 9 Expansion cohort in cHL Nivo 240 mg q 2 wk 1/2 2 Total 29
Investigative Urology, Baltimore
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Transactions of the Forty-ninth Annual Meeting of the Ohio State Medical Society,
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Banning tobacco billboards: The case for municipal action
Authors: D W Garner
Journal: JAMA (1996)

In 1994, Baltimore, Md, became the first city to generally prohibit billboards from displaying alcohol and tobacco advertisements. The owner of most of Baltimore's billboards, Penn Advertising, sued, but the federal district court rejected the billboard company's complaint and ruled that the First Amendment had not been violated and that the federal cigarette labeling acts had not preempted the ability of Baltimore to regulate and prohibit billboard cigarette advertising. In the fall of 1995, the federal district court's judgment was unanimously affirmed by the Fourth Circuit Court of Appeals in Richmond, Va. This article analyzes the constitutional and preemption issues and concludes that states and municipalities are on firm legal ground when they restrict the location or placement of publicly visible cigarette advertisements without attempting to regulate the advertisement's content or message. States and municipalities command broad authority to protect children and to shield the public from intrusive forms of advertisement that inflict their messages on a captive audience. A billboard ban thus offers local communities a legal avenue to help curb the rising tide of juvenile smoking without raising taxes, creating bureaucracy or angering smokers.
Critique and Cavil
Authors: George X. Trimble
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum
Journal: BMJ (1896)

out inflicting upon him the serious additional hardship of loss througlh the possession of unnecessary and useless uniforms.The recently qualified medical man does not thirst for military hionours, as can be seen from the paucity of competitors, and the uniform is purely a military matter, and imay well be dispensed with.Many more candidates would be forthcoming but for thlis fear of having to incur ulnnecessary expense when it can least be afforded. RANK ON VISITING CARDS.IN answer to a correspondenit, we apprehend an officer should not put any other than hlis true rank on hiis visiting cards.An officer who is surgeon-lieutenant-colonel is certainly not entitled to put surgeon- colonlel, whicll is a separate and a higher rank.